A diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
Authors (first, second and last of 25)
Volume 6, issue 3, June 2014
14 articles in this issue
-
-
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment
Authors (first, second and last of 6)
-
Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease
Authors (first, second and last of 4)
-
Cardiovascular medication burden in dementia disorders: a nationwide study of 19,743 dementia patients in the Swedish Dementia Registry
Authors (first, second and last of 6)
-
-
β-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice
Authors (first, second and last of 5)
-
Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab
Authors (first, second and last of 9)
-
-
Acetylation: a new key to unlock tau’s role in neurodegeneration
Authors (first, second and last of 5)
This is part of 1 collection:
-
-
The association of angiotensin-converting enzyme with biomarkers for Alzheimer’s disease
Authors (first, second and last of 9)
-
A coimmunization vaccine of Aβ42 ameliorates cognitive deficits without brain inflammation in an Alzheimer’s disease model
Authors (first, second and last of 14)
-
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
Authors (first, second and last of 12)
This is part of 1 collection:
-
